



Smile



2022

15 YEARS OF ENABLING LIFE SCIENCE INNOVATION

SmiLe is a non-profit life science business incubator helping early life science companies develop their business ideas and build successful companies within MedTech, BioTech, e-Health, Diagnostics and FoodTech.

SmiLe offers top-of-the-line business coaching, access to a large international network of investors and industry experts as well as access to a unique lab infrastructure consisting of eleven in-house laboratories with state-of-the-art instrumentation.

Since 2014 the Incubator companies together with Alumni companies have raised more than 717 MEUR in venture capital and 21 of the companies have launched IPO's.

SMILE AT A GLANCE 2022



717 MEURO
CAPITAL RAISED
SINCE 2014

5 
M&A'S

21 IPO'S 
SINCE START

100+ 
COMPANIES
1000+ PEOPLE



500 MEURO
MARKET CAPITAL
Q4 2022

29 
PORTFOLIO
COMPANIES

76 
GRADUATED
COMPANIES

39 
COMPANIES
LAUNCHED
PRODUCTS

86% 
STILL
GROWING



**EBBA
FÅHRAEUS
CEO**

“I AM PROUD OF OUR ACHIEVEMENTS AND DYNAMIC COMMUNITY”

A WORD FROM THE CEO

SmiLe Incubator, formerly known as Lund Life Science Incubator, has come a long way since its foundation in 2007 as Lund Bioincubator. When I took over as CEO in 2015, this was a small, regional incubator with a good infrastructure and dedicated, but very few, employees and limited resources. By revising the business model, re-branding and focusing on improving the processes and business coaching we have undergone a transformation and become an internationally recognized and highly successful life science incubator.

Today we have coached more than 100 companies to success, of which 21 have launched an IPO, and we have received ‘Excellent incubator’ status by Vinnova, a further testament to our success.

GROWING OUR OPERATIONS

Thanks to our founding partners, sponsors as well as generous donations, we have made significant progress in developing and growing our operations beyond the incubator program. By investing heavily in digital learning, we now offer several

international, virtual programs catering to both early-stage and more advanced startups. Recently we launched Biotech Bootcamp tailored for future European biotech entrepreneurs. This program is run together with German Bio^M and Merck, two major international life science players, and this is the first time we engage in an international cooperation on this scale.

UNIQUE LAB INFRASTRUCTURE

We have also been able to further develop and upgrade our unique lab infrastructure so that we can continue to offer our startups affordable access to state-of-the-art instrumentation. During the last few years, we have made significant investments in new equipment for developing modern biopharmaceutical drugs and supporting innovations in several exciting new areas such as ATMP, foodtech and probiotics, amongst others.

VENTURE CAPITAL AND IPO's

In 2021 we reached a significant, long-term milestone when we launched our own angel investment company SmiLe Inject Capital. We can now give innovative early-stage life science companies better access to venture capital and so far, we have already invested 14 million SEK in five promising startups.

Recently we also celebrated another milestone as the first company originating in SmiLe, Acrivon Therapeutics Inc., the parent company of SmiLe

alumnus Acrivon AB, rang the closing bell at the NASDAQ in New York, after having raised \$99 million in an IPO. This marks our 21st IPO and proves our ability to produce high-quality life science companies that are successful on a highly competitive global market.

KEY LIFE SCIENCE PLAYER

Looking back at our journey I am proud not only of our achievements but the dynamic and diverse community we have built. With over 350 years of life science expertise, more than 40 nationalities, 41% female founders and CEO's together with a large industry and investor network we have become a leading life science incubator and a key player in the Swedish life science ecosystem.

Going forward, SmiLe is committed to becoming a top life science incubator in Europe by expanding international partnerships and collaborating with industry leaders. By supporting early-stage companies in promising new fields within life science, as well as fostering a diverse and inclusive community, we aim to have an even greater impact on society.

I am grateful to all our members, partners and sponsors that have supported us over the years – by continuing to work together we will enable another 15 years of success for SmiLe.



15 YEARS OF HISTORY & MILESTONES

2011: Non-profit company established under the name Lund Life Science Incubator AB (LLSI).



2015: New CEO recruited.



2007

2008

2011

2012

2015

2007: A group of local authorities and firms (Innovationsbron Syd AB, Lund University, Ideon Center, Region Skåne, Lund Municipality and Sparbanksstiftelsen Färs & Frosta) agreed to establish the new Lund Bioinkubator (later Ideon Bioinkubator), which is the origin of SmiLe. The operation was located in new facilities at Biomedicinskt Centrum (BMC), Lund University.

2008: The trust, Stiftelsen inkubatorerna i Lund (STIL), was formally registered.

2012: The incubator moves to the newly established Medicon Village Science Park in the old Astra Zeneca premises.



2016: Rebranding and change of company name to SmiLe Incubator. Launch of an international accelerator program, Bootcamp (formerly known as H2B), with focus on digital health.



2017: Focusing on initiatives targeting industry and VC network initiatives.

2020: Awarded excellent incubator by Vinnova and granted maximum funding (2020-24).



2022: The 100th company enters SmiLe Incubator. Acrivon Therapeutics Inc. is the first company originating in SmiLe Incubator listed on NASDAQ New York.



2016

2017

2019

2020

2021

2022

2019: Investing in digital learning and program platform. International collaboration with EIT health funded project.



2021: Launch of the investment company Smile Inject Capital AB. Launch of Biotech Bootcamp in collaboration with the German life science cluster Bio^M and sponsored by Merck.



OUR PROGRAMMES

SmiLe offers business development programs and online educational courses for every stage and need.

We take you from teaching the key principles of life science industry and innovation to validating your business idea and developing your company and all the way through to supporting your growth and scale-up.




smiLe
e-CAMPUS

E-LEARNING FOR ASPIRING ENTREPRENEURS



smiLe
BOOTCAMP

INTENSIVE COURSE FOR EARLY STAGE STARTUPS



smiLe
INCUBATOR

DEVELOPMENT OF STARTUPS



smiLe
ACCELERATOR

GROWTH OF SCALE-UPS

START ||| FINISH

e-Campus is an 8 week online program designed for aspiring life science entrepreneurs in any field of the life sciences. Biotech, medtech, healthtech, e-health, pharma, diagnostics... you name it.

Healthtech Bootcamp is a 10 week intensive virtual development program for early-stage HealthTech, MedTech and eHealth start-ups.

Biotech Bootcamp is an 8 week business training program tailored to aspiring biotech entrepreneurs.

Incubator is a 1-5 -year business development program for startups in the concept development phase wanting to validate, develop and grow their business model.

Accelerator is our service offer to companies that has graduated from the incubation program. The alumnes have access to the community, network, trainings and facilities.

THE CORE OF OUR OFFERING

THE INCUBATOR PROGRAMME



As a leading business incubator in Europe, we support early-stage life science entrepreneurs with commercialization and business development to accelerate the development of new and innovative solutions that benefit people and society.

With our extensive inhouse experience and industry knowledge as well as well-defined business processes, we focus on each company's ultimate transactional goal and business outcome.

OUR EXTENSIVE INCUBATOR PROGRAMME IS THE CORE OF OUR BROAD OFFERING.

This 1-5 -year business development program is designed for startups in the concept development phase wanting to validate, develop & grow their business model.

A startup that has graduated from SmiLe's incubator program will have developed its innovation and management as well as business and corporate structure to the standard that is required to be able to engage with professional counterparts in the life science industry and investor community as well as customers.

OUR INCUBATOR PROGRAM OFFERS THE BEST IN:

COACHING

Benefit from our 350+ years of expertise from the life science industry that supports you in every step from science to market. The coaching is tailored to your business and innovation. Our thorough business development program encompasses building the business case, IP, licensing & partnering, pre-clinical & clinical verification, market validation and more.

CAPABILITIES

Make use of our 11 joint laboratories, which cover 350 m², equipped with state-of-the-art instruments for diagnostics and drug discovery. The facility also houses 1,700 m² private laboratories. Start working on your idea from day one – without having to invest in advanced instrumentation.

COMMUNITY

The SmiLe Community provides you with an open and collaborative environment where you grow and innovate alongside your peers. You work with life science innovators who share the same passion & drive and face similar challenges. Join professional community events and receive support and services from SmiLe's partners.

CAPITAL

Our experts have long experience of financing startups by grants and venture capital. Together we create a customized plan connected to your business model. We help you structure key assets and milestones to enable successful fund raising. When you are ready, we introduce you to relevant investor networks and stakeholders.



OUR LABS



At SmiLe we offer our member companies access to a unique lab infrastructure with 11 modern, in-house labs.

Our 350 square meter lab space houses 40 pieces of advanced equipment, as well as more than 60 smaller instruments such as centrifuges and scales.

We are continuously updating our equipment and premises. In recent years we have made significant investments thanks to substantial support from external funds. As a result we can offer our companies new technologies essential for developing modern biopharmaceutical drugs.

SUPPORT NEW AREAS

Some of our new equipment is supporting innovations in areas as foodtech, probiotics and ATMPs, i.e. advanced therapy medicines such as gene therapy and cell therapy. We have, for example, invested in bioreactor technology, and additional virus and cell culture equipment to meet the demands from start-ups developing ATMPs.

In addition, we have expanded our ability to support companies developing foodtech, sustainable foods and food supplements, by adding specific instruments for analysis of food characteristics.

We are also creating a dedicated microbiology lab space to support companies working with probiotics.

ESSENTIAL ANALYSES

Through our lab sponsor Agilent Technologies, we provide access to mass spectrometry instrumentation for extremely accurate analysis of most compounds relevant to drug discovery. With the additional support from our other lab sponsors, we can offer state-of-the-art instruments for a wide range of analyses.

These investments have been enabled by generous contributions from Mats Paulsson's Foundation for research, innovation and community building, Sparbanken Skåne's ownership foundation and the European Regional Development Fund. We also thank our lab sponsors Agilent Technologies, Phase Holographic Imaging and ChemoMetec.

smile INJECT CAPITAL

As all successful incubator environments worldwide are associated with capital, one of our long-term goals has been to be able to offer innovative life science companies in Southern Sweden even better access to venture capital.

In 2021 we reached this milestone when we founded SmiLe Inject Capital – the first angel investment company in Sweden that focuses solely on promising early-stage life science companies.

Through SmiLe Inject, we can offer private investors the opportunity to benefit from SmiLe's comprehensive life science expertise, international networks and unique insights into early-stage life science companies. The financing is provided by experienced business angels along with the state-owned venture capital company Saminvest. The aim is to invest EUR 3,9 million (SEK 40 million) in 10-15 promising life science companies over two years. In addition, we offer the opportunity for follow-on investments of a total of SEK 150 million.

Smile Inject Capital investments 2021-2022:

SAVGGY

SEK 4 million

MANJE
SIMPLIFYING HEALTHCARE

SEK 2 million

**Call
Knut**

SEK 2 million

Yazen

SEK 4 million

PHYSTEC

SEK 2 million



**THOMAS
UNT
CEO
SMILE INJECT
CAPITAL**

DIVERSITY - A KEY SUCCESS FACTOR

As diversity is strongly linked to both innovation and success, SmiLe works actively with promoting diversity both in our own team and in the member companies – and we walk the talk. By putting diversity on the agenda at an early stage, defining measurable KPIs and applying equal treatment, SmiLe has achieved fantastic results in the last few years.

41% ♀
**FEMALE CEOS
AND FOUNDERS**

As a lot of research also indicates that companies that have equal boards perform better in the long run, we want to give our companies the best possible prerequisites to build diverse and competitive companies that will be successful on a highly complex, international market.

By training the companies at an early stage, they are not only given tools to create diversity and equality but also to improve their success. Therefore, in 2021 we took on an even more difficult challenge of increasing the number of women in board positions as we participated in

50% ♀
**VENTURE CAPITAL
RAISED BY WOMEN**

Dagens Industri's Equality Challenge 365 – a one-year challenge where the participants work actively with their individual equality goals, supported by the Allbright Foundation.

During the year we ran a number of workshops with our member companies and the Allbright Foundation and the feedback was overwhelmingly positive. Many of the companies have shown great interest in running similar workshops for their own staff, which shows that we have really managed to create an understanding of how important this topic is.

OUR COMMUNITY

At SmiLe we take great pride in our diverse and dynamic community. In fact, this is something that our companies often bring up as one of the most valuable parts of being a SmiLe member.

With dozens of companies currently enrolled in our incubator and other programs, as well as an active alumni network and connections throughout the life science industries, SmiLe's members have a wealth of peers to turn to for ideas and inspiration.

Through our extended community our members can also connect with sponsors, industry partners and investors.

COMMUNITY EVENTS

Throughout the year we arrange a number of community events where our members have the opportunity to network and socialize with each other. For example our Wednesday breakfasts, where you can join either on-site or online, are extremely appreciated and a perfect opportunity to get the latest news and listen to inspiring presentations, while having a lovely breakfast with other community members.

40+ 
**NATIONALITIES
IN OUR COMMUNITY**

1000+ 
**PEOPLE MAKE UP
THESE COMPANIES**





FIRST COMPANY ORIGINATING IN SMILE INCUBATOR LISTED ON NASDAQ NEW YORK

December 14th 2022 marked yet another huge milestone as Acrivon Therapeutics Inc., the parent company of SmiLe alumnus Acrivon AB, rang the closing bell at the NASDAQ in New York after having raised \$99 million in an IPO.

Acrivon Therapeutics, Inc., is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine. This is possible by utilizing the company's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.

Headquartered in Boston, Acrivon Therapeutics Inc. is the parent company to Acrivon AB, an alumnus of SmiLe Incubator, originating in OncoSignature AB, a biotech start-up founded by Kristina Masson and Peter Blume-Jensen in 2016. Today, Acrivon AB is the company's Scandinavian hub where the early discovery research is largely conducted, and an active member of the SmiLe community.



"It's been a great experience to build and grow the company to this point, in both Sweden and the US, and we are very excited about reaching this important milestone. We are also grateful for all the support received by the Incubator here in Sweden, and look forward to continuing our partnership"

– Kristina Masson, co-founder of Acrivon Therapeutics Inc. and site head of Acrivon AB, the company's subsidiary in Lund.

RED GLEAD DISCOVERY



**JOHAN
EVENÅS**
**CO-FOUNDER
AND CEO**
**RED GLEAD
DISCOVERY**

Red Glead Discovery is a leading Scandinavian provider for integrated drug discovery contract research. The company offers expertise to biotech and pharma companies in the discovery and development of small molecule or peptide leads and clinical candidates. This year, Red Glead Discovery was awarded as Gazelle company for the 5th time by the leading Swedish business newspaper Dagens Industri, as one of the fastest growing companies in Sweden.

WHAT HAS HAD THE BIGGEST IMPACT?

“Since we started without investors, we had to learn how to sell early on, in order to get revenue. This led to an early focus on the customer’s needs which has been a successful strategy ever since. We have also been good at maintaining our independence, working hard and of course we have had a bit of luck now and again.”

HOW HAS SMILE CONTRIBUTED?

“There have been many good things over the years but there are three I especially want to highlight.

– All the opportunities SmiLe gives to socialize with other start-ups, and constantly exchange experiences that strengthen us all. Through all the various successes, both SmiLe and the SmiLe companies indirectly promoted each other, which has greatly benefited the entire SmiLe community.

– The access to a lab environment with certain types of instruments that we couldn’t afford to invest in ourselves in the beginning. Through SmiLe, we had the chance to rent labs and instruments in a flexible and cost-effective way.

– The opportunity to participate in various training courses and joint marketing efforts, for example through the Swedish Agency for Economic and Regional Growth (Tillväxtverket).”

YOUR BEST ADVICE TO STARTUPS?

“Involve the customer at an early stage. Don’t give away free samples, instead try to sell – the size of the transaction isn’t that important in the beginning. And don’t lose focus on your business idea.”

SMILE ALUMNI SUCCESS STORIES

NEOLA MEDICAL



**HANNA
SJÖSTRÖM**
CEO
NEOLA MEDICAL

Neola Medical's mission is to improve the life of pre-term born infants. The company is in the late stage of the development of a medical device for continuous lung monitoring of these prematurely born babies with an instant detection of lung complications. The current focus is to launch the product on the American market within two years.

YOUR KEY SUCCESS FACTOR?

"That we dared to have a laser sharp focus on developing a medical device that can improve the lives of pre-term born babies, in the clinic, as fast as possible. We have been working purposefully towards commercialization for the last four years."

SMILE'S MAIN IMPACT?

"SmiLe's coaches were instrumental during our IPO. I could call a coach at any time and expect expert advice from someone with no other agenda than wanting the best for our company. In addition, SmiLe's network, coaches and CEOs of other incubator companies opened the doors to Life Science Industry."

MAJOR MILESTONES LAST YEAR?

"A large investigator initiated clinical study on 100 newborn infants was successfully completed at Cork University Hospital in Ireland, which also was the first organization to purchase our lung monitoring system."

In addition, we are now certified according to ISO 13485 which means that we have a quality management system in place to sell our medical device internationally."

WHERE IS THE COMPANY HEADING?

"Our current focus is to prepare for the launch of our medical device on the U.S. market in 2024. We are in the final phase of the registration process required to start selling products in the U.S. with FDA. Next year, we will carry out clinical and technical studies that will form the basis of the company's technical file to the American authority."

TOP ADVICE FOR STARTUPS?

"Focus on building a profitable business from the start, that is develop the business as carefully as the technology, with the same priority and status."

ICONOVO



**OREST
LASTOW
CTO AND
FOUNDER
ICONOVO**

Iconovo has radically transformed inhaled drug therapy by developing unique inhaler devices with tailored dry powder formulations. The typical customer provides its drug molecule and gets ready-to-use drug inhalation products.

YOUR MOST CRITICAL MILESTONES?

“Our first important milestone was the agreement in 2016 with our first customer, Amneal Pharmaceuticals. Thanks to the signing fee we were able to hire staff and start operations. Next important milestone was the IPO in 2018, when we received capital that enabled us to hire more people and expand the business.”

SMILE’S MAIN CONTRIBUTION?

“Being part of a community of other entrepreneurs was very important in the beginning. We also collaborated with many of the SmiLe companies. In addition, SmiLe provided purpose-built laboratories that were tailored to our needs.”

YOUR ADVICE TO STARTUPS?

“You should have a plan already at an early stage for how you will commercialize the idea and make money. It is also important to know why you are the ‘best in the world’ at what you do, which will translate into confidence when meeting with clients.

Having a well-thought-out and clear business plan right from the start, and working towards it, makes it easier to attract investors.

It is not necessarily a bad thing to be a little bit naive in the beginning – if you are not aware of all difficulties you might encounter along the way; you dare to take more risks.”

MEET OUR PORTFOLIO COMPANIES

1 ACORAI

Acorai is redefining heart failure monitoring by developing a non-invasive intracardiac pressure monitor. The hardware with a four-sensor technology combined with a machine learning engine ensures superior signal quality and robustness across patient subtypes and clinical environments.

2 Ap.Glyx

Apoglyx is a pre-clinical stage company developing first-in-class Aquaporin-9 inhibitors with anti-inflammatory properties. Prioritized pipeline indications include solid tumors, intestinal perforation, and atopic dermatitis.

3 Amplio Pharma

Amplio Pharma is a pharmaceutical company that develops proprietary drug products that amplify the efficacy of pharmaceutical treatments in a significant manner. With its lead candidate, the company intends to double the number of patients benefitting from the 1st line rheumatoid arthritis treatment.

4 asgard THERAPEUTICS

Asgard Therapeutics is a spin-off from Lund University aiming to advance cancer immunotherapies by developing a paradigm-shifting gene therapy – TrojanDC. Asgard is developing the world's first cancer immunotherapy based on direct cell reprogramming, forcing cancer cells to become immunogenic and unleashing the immune system against cancer.

5 Call Knut

eHealth company **Call Knut** develops an AI based voice robot service that regularly calls elderly on an ordinary phone to check in and see that they are ok. Call Knut is a complement in communicating with and caring for elderly people in, for example, elderly care.

6

Cirkulär is developing the next generation of biological factories – powered by fungal cells. The versatile technology platform enables the company to help serve various purposes and industries that embrace sustainable transformation.



7 **LBM Sweden** develops specialty magnesium alloys enabled by a unique technology for the fabrication of biodegradable implants. The alloy facilitates the healing process and disappears through normal physiological mechanisms, reducing the need for further surgeries.



8 **Manje Health** commercializes its new digital platform that makes the process of searching, identifying and booking specialized treatment for chronic diseases across Africa easily accessible. The digital platform provides convenience and saves time and money.



9 **Medilevel** commercializes its tool for medicine titration and self-monitoring. It can easily be adapted to a wide range of different medications and is today used by healthcare in ADHD and depression. The resource-efficient tool increases patient compliance and decreases side effects.



10 **Medow's** product, the IV-bracelet, keeps tubes in place during intravenous treatments, so that the patients can move around without discomfort or complications and the nurses' work become more efficient.



11 **Medotemic** develops advanced systems for analysis of walking and running. The movement pattern is analyzed in detail by processing sensor data from the mobile phone.



12 **MedVasc** has developed Solutio, a patented medical device that reduces pain when treating varicose veins. The innovative treatment procedure requires only one cut through the patient's skin and encloses both a laser fibre and an anesthetic needle. The project is currently in clinical phase.

A WORD FROM OUR ALUMNI

IN2CURE AND XINNATE

In2cure is one of our spin-offs from Lund University. The co-founder's research has resulted in proprietary platform technology which consists of specific peptides appearing in nature's host defense. Its subsidiary Xinnate has developed a lead candidate that is currently in clinical trials for inflammatory skin diseases.

"The support of the SmiLe business coaches and the SmiLe community has been instrumental when developing the company."

Helene Hartman, Co-founder and CEO

13



Nordic Rebalance develops foods that contribute to a good intestinal environment, which promotes good health. The company's product ReFerm is a postbiotic, recommended to be taken in case of intestinal problems, IBS or inflammation of various degrees.

14



Nygen Analytics has launched a cloud-based software service, ScarfWeb, which makes it easy for researchers to analyze genomic data of individual cell types (single cells) from biological tissue.

15



Pharmista Technologies are on a mission to revolutionize women's health by disrupting the pregnancy testing market. The company develops a reusable pregnancy test that is based on patented platform technology.

16



Phystec commercializes its digital tool Pedatim that personalizes rehabilitation and shortens hospital stay. This easy-to-use tool motivates patients, and facilitates compliance and monitoring of, for example, post-surgical rehabilitation.

17



Prebona Healthcare offers a toolbox of possibilities to help reduce malodors and healthcare-associated infections in a safe and responsible way. Prebona's solutions for infection prevention are applicable on a wide range of materials and help surfaces stay more hygienic.

18



rAAVen Therapeutics wants to help pave the way for the next generation of gene therapies. The company uses cloning, virus variant production and sequencing to build novel viral vectors for precision targeting of defined cell populations or with desired properties.

19



Saveggy is revolutionizing the food coating industry. The company's sustainable bio-based, edible and vegan coating extends the shelf life of fresh fruits and vegetables, and has potential to replace today's fossil-based plastic coatings.

20



Selcis BioPharma develops a technology where SCFAs, short chain fatty acids, can be delivered to the colon and potentially prevent or restore gut homeostasis. SCFAs are considered to promote good gastrointestinal health.

21



Sinntaxis is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke. The company has an established discovery platform for preclinical studies of stroke recovery.

22



Sorbus Biomedical intends to induce a paradigm shift in how cultivated cells can be used in life science research and healthcare. The company develops a novel biotech equipment that radically improves the function of cultivated cells.

23



Starfish of Sweden has developed a platform to shield patients from conditions known to lead to pressure ulcers, a painful condition that is difficult to treat. Starfish of Sweden is developing a broad product portfolio, ready for the market needs of the future.

24



Tekinn provides a technology platform for improving the quality of life of people and the planet. It enables circular flows of organic side streams to become sustainable and profitable products, such as nutritious foods, across many industries.

25



TIGERQ

TIGERQ offers a full scope gene-editing analysis solution that combines proprietary sequencing algorithms in a SAAS solution for Pharma and Healthcare.

26

UMAN
SENSE

UmanSense develops Stroke Alarm, a pioneering technology for early detection of stroke, consisting of two wristbands with sensors for wireless communication. With its AI-based software, the product detects if the user is having a stroke and then sends an alarm so that help can be provided quickly.

27



Antibiotic resistance is an increasing global problem. **Xaga Surgical** develops a new breed of medical needles that will save the lives and health of patients in the era of antibiotic resistance. The company's prostate biopsy needle reduces the bacterial transmission by 96% and thereby reduces the risk of a severe infection.

28



Xinnate

The research of **Xinnate's** co-founder at Lund University has resulted in proprietary platform technology within advanced wound care, which consists of specific peptides appearing in nature's host defense. The company has developed a lead candidate that is currently in clinical trials for inflammatory skin diseases.

29

Yazen

Yazen Health is a pioneering eHealth clinic for obesity treatment in Europe. The company offers a holistic digital healthcare service that combines medication, lifestyle changes and diet to support obese patients to reach and maintain a healthy weight.

A WORD FROM OUR ALUMNI

IMMUNOVIA

While at SmiLe, Immunovia gained access to a broad life expertise, valuable infrastructure with laboratories and closeness to Lund University. The company's product IMMray™ PanCan-d is the first blood-based test on the market dedicated to early detection of pancreatic cancer.

"SmiLe's internationalization experience and commercial community is crucial for a startup."

Carl Borrebaeck, PhD Founder of Immunovia

smile TEAM & BOARD



**EBBA
FÄHRAEUS**
CEO



**LINA
OLSEN BORESON**
COO



**OLA
SKANUNG**
CFO



**PER
BRUNMARK**
Director Core Facilities
& Business Coach



**THOMAS
UNT**
CEO Smile Inject Capital
& Business Coach



**ISAK
SIMONSSON**
Project Manager



**LAURA
BEJTULAI**
Project & Platform
Manager



**JACOB
LUNDGREN**
Jr. Financial Business
Manager



**ÅKE
BENGTSSON**
Senior Business
Advisor



**FRIDA
FRANSSON**
Project Manager



**KÅRE
ENGLIDE**
Senior Business
Advisor



**KRISTIAN
ENKVIST**
Project Portfolio Lead
& Senior Advisor



**MARTINA
SCHNEIDER**
Senior Application
Scientist



**ANKI
MALMBORG HAGER**
Business Coach



**SARA
WANThER**
Project Manager



**ULRIKA
AXELSSON**
Business Coach



**CHRISTEL
WÅNGNERUD**
Administration
Manager



**LOTTA
LJUNGBERG**
Business Coach



**THOMAS
ARESCHOUG**
Business Coach



**MARINA
NILSSON**
Administration
Manager



**TOMAS
ERIKSSON**
Business Coach



**BARBARA
KLEIN**
Project Manager



**MALIN
SJÖ**
Business Developer



**ANDERS
WRÄMNER**
People & Culture
Coach



**ELISABET
OTTOSON**
Communications
Manager



**MARIA
GALVIN**
Head of Communications
& Marketing



**ULRIKA
RINGDAHL**
Senior Advisor

BOARD OF DIRECTORS

Pia Kinhult, Chairwoman
Head of Host
States Relations,
European Spallation
Source

Per Persson
Director of Trade
and Industry,
City of Lund

Petter Hartman
CEO, Medicon Village
Innovation AB

Jeremie Poirier
Venture Capital at
Region Skåne

Niclas Nilsson
LU Innovation

FOUNDERS & SPONSORS

FOUNDERS



SPONSORS

DIAMOND LAB SPONSOR

PLATINUM PARTNER SPONSOR



GOLD PARTNER SPONSOR

GOLD PARTNER SPONSOR

GOLD PARTNER SPONSOR

PROGRAM SPONSOR



GOLD PARTNER SPONSOR

GOLD PARTNER SPONSOR

GOLD PARTNER SPONSOR



GOLD LAB SPONSOR

GOLD LAB SPONSOR

FRIEND LAB SPONSOR



WITH FUNDING FROM





SMILEINCUBATOR.LIFE